Milestone Pharmaceuticals Receives FDA Approval for CARDAMYST™ (etripamil) Nasal Spray for PSVT

The FDA has approved Milestone Pharmaceuticals' CARDAMYST™ (etripamil) nasal spray for treating adults with paroxysmal supraventricular tachycardia (PSVT). This is the first self-administered, rapid-acting treatment for the condition, which affects over two million Americans, allowing them to manage episodes outside of a healthcare setting. The company anticipates receiving a $75 million milestone payment upon this approval.